Ann: Executive Change, page-4

I see the changes as a positive. Brian is a proven bring to market guy (I.e. get it listed, bet the ball rolling), but not a "commercialiser" for lack of a better work. And as technically competent as Dr Andrews is, I never saw her role in a CEO capacity getting much past phase 2 trials commencing. It is great that she will stay on in a COO capacity to oversee the trials, particularly as it provides continuity with ongoing regulatory discussions.

NTI Needs an out and out deal maker from here to maximise shareholder value. The drug works, more trials will prove that up with more confidence. IT is about getting the bidding war started... These are all required changes.